Home Cart Sign in  
Chemical Structure| 149402-51-7 Chemical Structure| 149402-51-7

Structure of HPPH
CAS No.: 149402-51-7

Chemical Structure| 149402-51-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

HPPH is a second generation photosensitizer, which acts as a photodynamic therapy (PDT) agent

Synonyms: Photochlor; Pyropheophorbide-α-hexyl-ether; 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of HPPH

CAS No. :149402-51-7
Formula : C39H50N4O4
M.W : 638.84
SMILES Code : O=C(O)CC[C@@H]([C@@H]/1C)C2=NC1=C/C3=C(C)C(C(OCCCCCC)C)=C(N3)/C=C4C(C)=C(CC)/C(N/4)=C/C5C(C)=C6C(N5)=C2CC6=O
Synonyms :
Photochlor; Pyropheophorbide-α-hexyl-ether; 2-(1'-hexyloxyethyl)-2-devinylpyropheophorbide-a.
MDL No. :MFCD11040935
InChI Key :PUUBADHCONCMPA-USOGPTGWSA-N
Pubchem ID :148160

Safety of HPPH

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CT26 cells 1 µg/mL 1, 2, 4 hours Evaluate the cellular uptake efficiency of CPT-TK-HPPH/Pt NP, results showed increased fluorescence signal over time Adv Sci (Weinh). 2020 Sep 6;7(20):2001853
MCF-7 0.025 mg/mL 10 minutes Evaluate the cytotoxicity and photodynamic therapy effect of HPPH on MCF-7 cells in vitro. Results showed that HPPH significantly reduced cell viability under 660 nm light irradiation. J Nanobiotechnology. 2021 May 19;19(1):147
MDA-MB-231 0.025 mg/mL 10 minutes Evaluate the cytotoxicity and photodynamic therapy effect of HPPH on MDA-MB-231 cells in vitro. Results showed that HPPH significantly reduced cell viability under 660 nm light irradiation. J Nanobiotechnology. 2021 May 19;19(1):147
BT-474 cells 0.15–40 μg/mL 24 hours To evaluate the cytotoxicity of HPPH, results showed significant cytotoxicity when the concentration of HPPH increased to 20 μg/mL. Int J Nanomedicine. 2023 Jan 19;18:339-351
LLC cells 1.5 μM 24 hours To evaluate cellular uptake and fluorescence enhancement of HPPH-loaded nanoparticles. Heating to 40°C increased HPPH fluorescence signal by ~2.5-fold. Nanoscale Adv. 2025 Jan 9;7(7):1946-1961

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Colon cancer model Intravenous injection 25 µg HPPH/mouse Single injection, observed up to 48 hours Evaluate the in vivo distribution and tumor targeting ability of CPT-TK-HPPH/Pt NP, results showed significant fluorescence and photoacoustic signals at tumor sites Adv Sci (Weinh). 2020 Sep 6;7(20):2001853
BALB/c nude mice MDA-MB-231 tumor model Tail vein injection 5 mg/kg Single treatment Evaluate the antitumor effect and fluorescence imaging capability of HPPH in vivo. Results showed that the CO-HPPH-TH302/Lipo group exhibited significantly enhanced fluorescence signals in the tumor area and better antitumor effects compared to other groups. J Nanobiotechnology. 2021 May 19;19(1):147
Zebrafish Zebrafish embryos and larvae Exposure in embryo medium 250 µM From 5.25 hpf to 120 hpf To assess the morphological outcomes and potential bioactivation of two anti-epileptic drugs, CBZ and PHE, in zebrafish embryos during organogenesis from 5? hpf to 120 hpf. The results showed teratogenic effects for CBZ and PHE, but not for HPPH. Int J Mol Sci. 2021 Nov 24;22(23):12696
Athymic Ncr-nu/nu female mice Non-small cell lung cancer intrathoracic dissemination model Tail vein injection 0.5 or 1 mg/kg HPPH Single dose, illumination performed 24 hours later To study the efficacy of HPPH-mediated photodynamic therapy at different fluence rates (75 vs 150 mW/cm) in reducing the burden of non-small cell lung cancer and the activation of epidermal growth factor receptor (EGFR) in areas of post-treatment proliferation. Results showed that the low fluence rate of 75 mW/cm produced the largest reductions in tumor burden, while increased EGFR activation in proliferative areas was detected only after treatment at the higher fluence rate of 150 mW/cm. Int J Mol Sci. 2016 Jan 14;17(1):101
BALB/c nude mice LLC tumor model Intratumoral injection 0.4 mg/kg Single injection, observed up to 63 hours To evaluate fluorescence enhancement of HPPH-loaded nanoparticles in tumors. Significant fluorescence enhancement post-heating suggests potential for imaging-guided photodynamic therapy. Nanoscale Adv. 2025 Jan 9;7(7):1946-1961
NSG-SGM3 mice Patient-derived xenograft (PDX) model Tail vein injection 200 uL HPPH-liposomal formulation Single dose, laser treatment 4 hours post-injection Evaluate biodistribution and efficacy of HPPH-liposomes in PDX models. Results showed tumor-specific accumulation of HPPH-liposomes, with significant tumor growth reduction and necrosis post-laser treatment. Oral Oncol. 2023 Sep;144:106487
Mice 4T1 and A549 tumor models Intravenous injection 0.32 mg/kg Single dose Evaluate the photodynamic therapeutic effect of HPPH in vivo, results showed that HPPH effectively inhibited tumor growth and prolonged animal survival at low dosage. ACS Pharmacol Transl Sci. 2021 Feb 4;4(2):802-812

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00025571 Lung Cancer PHASE1 COMPLETED 2025-10-04 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263-0001, United States Less <<
NCT01140178 Dysplasia|Carcinoma of the Ora... More >>l Cavity|Carcinoma of the Oropharynx Less << PHASE1 COMPLETED 2018-10-01 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263, United States Less <<
NCT00670397 Head and Neck Cancer PHASE1 TERMINATED 2025-07-15 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263-0001, United States Less <<
NCT00281736 Esophageal Cancer|Precancerous... More >> Condition Less << PHASE2 COMPLETED 2025-12-13 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263-0001, United States Less <<
NCT01238042 Barrett's Esophagus|CIS|HGD PHASE1 COMPLETED 2025-11-14 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263, United States Less <<
NCT00526461 Lung Cancer PHASE1 COMPLETED 2025-04-14 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263-0001, United States Less <<
NCT00017485 Non-melanomatous Skin Cancer PHASE1 COMPLETED 2025-01-07 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263-0001, United States Less <<
NCT00060268 Esophageal Cancer PHASE1|PHASE2 COMPLETED 2025-06-04 Roswell Park Cancer Institute,... More >> Buffalo, New York, 14263-0001, United States Less <<
NCT01236443 Barrett's Esophagus|CIS|High G... More >>rade Dysplasia Less << PHASE1 COMPLETED 2025-04-13 Roswell Park cancer institute,... More >> Buffalo, New York, 14263, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.57mL

0.31mL

0.16mL

7.83mL

1.57mL

0.78mL

15.65mL

3.13mL

1.57mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories